Table 2. Indications/clinical scenarios and supporting studies which warrant use of ribavirin.

Patient Population	Regimen	Study
GT1a and GT1b, non-cirrhotic, treatment-naïve	PrOD+RBV for 12 weeks	SAPPHIRE-I26
GT1a, non-cirrhotic, treatment-naïve	PrOD+RBV for 12 weeks	PEARL-IV27
GT1, non-cirrhotic, treatment-experienced	PrOD+RBV for 12 weeks	SAPPHIRE-228
GT1a, with or without compensated cirrhosis, treatment-naïve or treatment-experienced with protease inhibitor, with baseline NS5A RASs	EBR/GZR+RBV for 16 weeks	C-EDGE29,30 and C-SALVAGE31
GT1, compensated cirrhosis, treatment-experienced with interferon	LDV/SOF+RBV for 12 weeks	SIRIUS32
GT3, compensated cirrhosis, treatment-experienced with interferon	SOF/VEL+RBV for 12 weeks	Pianko et al.33
GT4, non-cirrhotic, treatment-naïve and treatment-experienced	PrO+RBV for 12 weeks	PEARL-I34
All genotypes, decompensated cirrhosis, treatment-naïve and treatment-experienced (except with NS5A or NS5B inhibitor)	SOF/VEL+RBV for 12 weeks	ASTRAL-435
Post-liver transplant GT 1, 4, 5, 6 (including decompensated cirrhosis)	LDV/SOF+RBV for 12 weeks	SOLAR-1,36 HCV-TARGET,37 and Kwok et al.38
Post-liver transplant GT 2, 3 (compensated cirrhosis only)	DCV/SOF+RBV for 12 weeks	ALLY-1,39 and Fontana et al.40